SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in fireside chats at the 6^th Annual Evercore ISI HealthCONx Conference in Miami, Florida and the Piper Sandler 35^th Annual Healthcare Conference in New York City.

Details of the fireside chats are as follows:

6^th Annual Evercore ISI HealthCONx Conference:
Date: Tuesday, November 28, 2023
Time: 3:50 p.m. Eastern Time

Piper Sandler 35^th Annual Healthcare Conference:
Date: Thursday, November 30, 2023
Time: 8:00 a.m. Eastern Time

The live and archived webcast of both fireside chats will be accessible on the Events & Presentations page in the Investors section on the Crinetics’ website at www.crinetics.com/events.

If you are interested in arranging an in-person 1×1 meeting with management, please contact your Evercore or Piper conference representatives.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Paltusotine, an investigational, first-in-class, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894 a first-in-class, investigational, oral ACTH antagonist, that is currently in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing’s disease. All of the Company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease, thyroid eye disease, hyperinsulinism, diabetes and obesity.

Contacts:
Chas Schultz
VP, IR & Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
(858) 450-6464

Investors:
Corey Davis
LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
(212) 915-2577

Media:
Jenn Gordon
Spectrum Science
This email address is being protected from spambots. You need JavaScript enabled to view it.
(202) 957-7795